Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Emeline R. Chong"'
Autor:
Guido Ghilardi, Luca Paruzzo, Vrutti Patel, Jakub Svoboda, Emeline R. Chong, Eugenio Fardella, Elise A. Chong, Giulia Gabrielli, Sunita D. Nasta, Daniel J. Landsburg, Jordan Carter, Raymone Pajarillo, Stefan K. Barta, Griffin White, Elizabeth Weber, Ellen Napier, David L. Porter, Alfred L. Garfall, Stephen J. Schuster, Marco Ruella
Publikováno v:
Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-5 (2024)
Abstract Bendamustine has been retrospectively shown to be an effective and safe lymphodepletion regimen prior to the anti-CD19 chimeric antigen receptor T cell (CART) products tisagenlecleucel and axicabtagene ciloleucel, as well as the anti-BCMA CA
Externí odkaz:
https://doaj.org/article/7841086f48d141fcacd16214fbafb379
Autor:
David L. Porter, Emeline R. Chong, Stefan K. Barta, Stephen J. Schuster, Noelle V. Frey, Sunita D. Nasta, Alfred L. Garfall, Jakub Svoboda, Daniel J. Landsburg, Elise A. Chong, Marco Ruella, James N. Gerson, Elizabeth Weber
Publikováno v:
Blood. 136:19-20
Introduction: High-grade B cell lymphoma (HGBCL) with rearrangements of MYC in addition to either BCL2 or BCL6 (DHL) generally has a poor prognosis for response to conventional therapies. Nevertheless, current studies of responses to anti-CD19 CAR-T
Autor:
Don L. Siegel, Noelle V. Frey, Carl H. June, Shannon L. Maude, Stephan A. Grupp, Emeline R. Chong, Elise A. Chong, David L. Porter, Bruce L. Levine, Whitney L. Gladney, Wei-Ting Hwang, Megan M. Davis, Stephen J. Schuster
Publikováno v:
Blood
Autor:
Daniel J. Landsburg, Stephen J. Schuster, S. Nasta, Emeline R. Chong, Bruce L. Levine, Carl H. June, David L. Porter, Elise A. Chong, Jakub Svoboda, Nicole Winchell
Publikováno v:
Hematological Oncology. 37:137-138
Autor:
Abass Alavi, Drew A. Torigian, Elise A. Chong, Emeline R. Chong, Stephen J. Schuster, Sunita D. Nasta, Jakub Svoboda
Publikováno v:
Blood. 118:4204-4204
Abstract 4204 Introduction: Most patients with asymptomatic advanced-stage low grade follicular lymphoma (FL) are managed by a ”watch and wait” strategy until they develop disease related symptoms or significant progression in tumor volume. The m